Skip to main content
. 2014 Mar 14;122(6):616–623. doi: 10.1289/ehp.1307201

Table 2.

ORs (95% CIs) of incident T2D by quartiles of urinary concentrations (μg/L) of BPA: the NHS and NHSII.

Variable Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) ptrend
NHS/BPA
Median (range) 0.7 (0.03–1.0) 1.2 (1.0–1.5) 2.0 (1.5–2.7) 4.4 (2.8–56.1)
Case/control (n) 102/99 95/98 98/98 99/98
Model 1a 1 0.92 (0.62, 1.37) 0.85 (0.56, 1.29) 0.81 (0.52, 1.26) 0.40
Model 2b 1 0.99 (0.63, 1.54) 0.96 (0.60, 1.53) 0.77 (0.47, 1.26) 0.25
Model 3c 1 0.91 (0.56, 1.48) 0.98 (0.60, 1.61) 0.81 (0.48, 1.38) 0.45
NHSII/BPA
Median (range) 0.9 (0.03–1.3) 1.7 (1.3–2.0) 2.7 (2.0–3.5) 5.4 (3.5–45.4)
Case/control (n) 132/144 132/144 154/145 159/144
Model 1a 1 0.97 (0.69, 1.37) 1.09 (0.77, 1.54) 1.10 (0.76, 1.59) 0.54
Model 2b 1 1.08 (0.72, 1.61) 1.29 (0.86, 1.94) 1.40 (0.91, 2.15) 0.13
Model 3c 1 1.34 (0.70, 2.27) 1.91 (1.11, 3.29) 2.08 (1.17, 3.69) 0.02
aIn model 1, we automatically adjusted for matching factors, including age at urine sample collection, ethnicity, fasting status, and time of sample collection, menopausal status, and use of hormone replacement therapy (NHSII only), by using conditional logistic regression, and also for urinary creatinine levels. bBased on model 1, we adjusted model 2 for smoking status, postmenopausal hormone use (NHS only), oral contraceptive use (NHSII only), physical activity, alcohol use, family history of diabetes, history of hypercholesterolemia or hypertension, and AHEI score. cBased on model 2, we adjusted model 3 for BMI.
HHS Vulnerability Disclosure